San Diego's Ambrx, Inc. Files For $86 Million IPO To Advance Antibody-Drug Conjugates
Published: May 07, 2014
San Diego-based Ambrx, a biotech company with a new approach to developing protein therapeutics for treating, cancers, diabetes, and other diseases and disorders, plans to raise as much as $86 million in an IPO, according to a regulatory filing that was made public Friday [May 2, 2014]. The company submitted its IPO plans confidentially on March 28th. Using recombinant DNA-based protein biosynthesis, Ambrx can insert non-native amino acids at precisely selected sites in native proteins as they are being made within the cells.
Help employers find you! Check out all the jobs and post your resume.